Premium
Pharmacoeconomics of Gastrointestinal Drug Utilisation Prior and Post Helicobacter pylori Eradication
Author(s) -
Klok Rogier M.,
Van Der Veen Willem Jan,
Van Der Werf Ger Th,
Van Den Berg Paul B.,
Brouwers Jacobus R. B. J.,
Postma Maarten J.
Publication year - 2004
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/j.1083-4389.2004.00202.x
Subject(s) - medicine , helicobacter pylori , pharmacoeconomics , medical prescription , drug , gastroenterology , peptic ulcer , intensive care medicine , pharmacology
Background. Eradication of Helicobacter pylori prevents recurrence of peptic ulcer. In pharmacoeconomic analyses it is often presumed that after successful eradication no more gastrointestinal drugs are used. We investigated this presumed positive monetary effect using General Practitioners prescribing data, including information in diagnosis. Methods. From the RNG‐database we identified patients with a H. pylori eradication in the years 1997–2000. H. pylori eradication was defined as a prescription of two antibiotics and one gastrointestinal drug on the same day. Patients were divided into a group with diagnosed ulcers and a group without diagnosed ulcers. Gastrointestinal drug costs were calculated for 4 months prior to eradication and 9–12 months post eradication. For comparison costs in all periods were expressed per patient per period. For statistical analysis the paired t ‐test was used. Results. One hundred and two patients were eligible for evaluation. Of these patients 35 had a diagnosed ulcer and 67 had not. Generally the number of patients on gastrointestinal drugs decreased (61% prior vs. 33% post), however, the drug costs did not change (€33 prior vs. €34 post). Costs for proton pump inhibitors increased post eradication (€14 prior vs. €28 post). The ulcer and nonulcer group showed similar results. Conclusion. Helicobacter pylori eradication is thought to be cost effective, however, we did not find a decrease in costs for all gastrointestinal drugs. There may be a great pharmacoeconomical advantage when it is possible to predict which patients are more likely to ‘fail’ eradication therapy.